-
N&PD Moderators: Skorpio | someguyontheinternet
Strattera - affinities?
- Thread starter C10H12N20
- Start date
Riemann Zeta
Bluelighter
It wouldn't. Reboxetine is not sold in North America, however. It is only available in the EU. In theory, they both should block NA transporters in the PFC, increasing available extracellular dopamine in the PFC. Remember that tomoxapine is not an anti-ADD drug, it is an anti-depressant that is marketed as an anti-ADD drug. High-dose bupropion (450mg) would probably have the same efficacy.
Last edited:
Scaphander
Greenlighter
how about psychedelic drugs like acid/shrooms ?
in my (very limited) understanding of these neuronal activities, the noradrenaline (thats the german name, i think it's norephiphrene in english?!) should "kill" a lot of the effects.
how about RC's like 2c-i, 2c-b etc. ?
oh, one last question: whats the difference between atomoxetine and reboxetine?
i'm thinking about to kick of Ritalin and try one of these for a short period
in my (very limited) understanding of these neuronal activities, the noradrenaline (thats the german name, i think it's norephiphrene in english?!) should "kill" a lot of the effects.
how about RC's like 2c-i, 2c-b etc. ?
oh, one last question: whats the difference between atomoxetine and reboxetine?
i'm thinking about to kick of Ritalin and try one of these for a short period
New Data Suggest Once-Daily Atomoxetine May Provide Symptom
2005-05-24 15:00 (New York)
Relief for Up to 24 Hours
Data Showed that Morning and Evening Dosing Produced Similar Results
ATLANTA, Ga., May 24 /PRNewswire-FirstCall/ -- Once-daily treatment with
atomoxetine HCl, approved for the treatment of Attention-Deficit/Hyperactivity
Disorder (ADHD), produced core symptom reductions in children and, in a
secondary analysis, were sustained up to 24 hours according to a study
presented today at the 158th annual meeting of the American Psychiatric
Association.
Atomoxetine was dosed in either the morning or the evening. This study
found morning or evening dosing produced similar core symptom reduction based
on the ADHD-RS, a scale which assesses 18 individual symptoms related to ADHD
(nine assess inattentive symptoms and the other nine assess hyperactive and
impulsive symptoms). This is the second placebo-controlled study that found
atomoxetine was effective in providing continuous symptom relief in children.
"Atomoxetine's ability to control symptoms of ADHD demonstrated in this
study for up to 24 hours provides physicians with a flexible option for
treating ADHD in children," said Humberto Quintana, Associate Professor of
Psychiatry, Louisiana State University School of Medicine at New Orleans, and
a lead investigator on the study.
Additional Study Results
* Both morning and evening dosing produced significantly greater
decreases than placebo at endpoint on the following scales:
- ADHDRS total score: 17.76 (41 percent) improvement with morning
dosing, 13.45 (32 percent) improvement with evening dosing, vs. 9.51 (22
percent) with placebo. Overall comparison with placebo p<.001 for morning
dosing, p=.009 for evening dosing.
- Daily Parent Rating of Evening and Morning Behavior-Revised Scale
Total (DPREMB-R), a secondary analysis: 3.61 (26 percent) improvement with
morning dosing, 4.85 (32 percent) improvement with evening dosing vs. 2.66 (17
percent) improvement with placebo. Overall comparison with placebo p=.028 for
morning dosing, p=.023 for evening dosing.
- Conners' Global Index: Parent-Morning scale (CGIP-M) Total, a
secondary analysis: 5.62 (34 percent) improvement with morning dosing, 6.02
(39 percent) improvement with evening dosing vs. 4.10 (26 percent) improvement
with placebo. Overall comparison with placebo p=.023 for morning dosing,
p=.024 for evening dosing.
- Conners' Global Index: Parent-Evening scale (CGIP-E) Total: 5.82 (31
percent) improvement with morning dosing, 4.46 (23 percent) improvement with
evening dosing vs. 2.03 (11 percent) improvement with placebo. Overall
comparison with placebo p<.001 for morning dosing, p=.002 for evening dosing.
* The most common treatment adverse events reported for patients on
atomoxetine included upper abdominal pain, decreased appetite, vomiting,
headache, somnolence, nausea and stomach discomfort.
"Atomoxetine offers the convenience of morning or evening dosing, allowing
parents to work with physicians to decide what dosing regimen best fits into
their child's daily routine," said Douglas Kelsey, MD, Senior Research
Physician, Eli Lilly and Company.
Methods
* 288 children (aged 6-12) were randomized to receive atomoxetine in the
morning and placebo in the evening (n=102), placebo in the morning and
atomoxetine in the evening (n=93) or placebo in the morning and evening (n=93)
for approximately six weeks. (Approved dosing is once or twice daily).
* Patients receiving atomoxetine (n=195) had a starting dose of
8mg/kg/day for three days and increased to the target dose of 1.2 mg/kg/day
thereafter. Maximum dose was 1.4 mg/kg/day but did not exceed 100mg
regardless of patient's weight. (Approved starting label dose is 0.5mg/kg/day
for children and adolescents up to 70kg).
* Parent assessments of children's home behaviors in the evening and
early morning were collected using the DPREMB-R and CGIP-M and CGIP-E scales.
About ADHD
ADHD affects three - seven percent of school-age children and manifests
itself in levels of attention, concentration, activity, distractibility and
impulsivity that are inappropriate to the child's age.(1) In addition, 60
percent of children with the disorder carry their symptoms into adulthood.(2)
Experts estimate four percent of adults in the United States, more than eight
million people, have ADHD.(3,4)
About Atomoxetine
Atomoxetine, a selective norepinephrine reuptake inhibitor, is approved to
treat ADHD in children aged six and over, adolescents, and adults. It is not
known precisely how atomoxetine reduces ADHD symptoms, but scientists believe
it works by blocking or slowing reabsorption of norepinephrine, a chemical in
the brain considered important in regulating attention, impulsivity and
activity levels. This keeps more norepinephrine at work in the spaces between
neurons in the brain. Improved efficiency in the norepinephrine system is
associated with improvement in symptoms of ADHD (Pliska, 1996).
Atomoxetine should not be taken at the same time as, or within two weeks
of taking, a monoamine oxidase inhibitor (MAOI) or by patients with narrow
angle glaucoma. Patients with a history of high or low blood pressure,
increased heart rate, or any heart or blood vessel disease should tell their
doctor before taking atomoxetine. Atomoxetine has not been tested in children
less than six years of age or in geriatric patients. Some children may lose
weight when starting treatment with atomoxetine. As with all ADHD
medications, growth should be monitored during treatment. Atomoxetine can
cause liver damage in rare cases. Patients should tell their doctor right
away if they have itching, dark urine, yellow skin/eyes, upper right-sided
abdominal tenderness, or unexplained "flu-like" symptoms.
Most people in clinical studies who experienced side effects were not
bothered enough to stop using atomoxetine. The most common side effects in
children and adolescents in medical studies were upset stomach, decreased
appetite, nausea and vomiting, dizziness, tiredness and mood swings. In
adults, the most common side effects were constipation, dry mouth, nausea,
decreased appetite, dizziness, problems sleeping, sexual side effects,
problems urinating and menstrual cramps.
About Lilly
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered in
Indianapolis, Ind., Lilly provides answers -- through medicines and
information -- for some of the world's most urgent medical needs. Additional
information about Lilly is available at www.lilly.com .
P-LLY
(1) American Psychiatric Association: Diagnostic and Statistical Manual
of Mental Disorders, fourth edition, text revision, Washington, DC, American
Psychiatric Association, 2000.
(2) Schweitzer JB, et al. Attention-deficit/hyperactivity disorder. Med
Clin of North Am. 2001; 85(3): 757-777
(3) Murphy K, Barkley, RA. J Atten disord. 1996; 1:147-161.
(4) United States Census Summary File; 2000.
(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )
SOURCE Eli Lilly and Company
CONTACT:
Jennifer Bunselmeyer of Eli Lilly and Company, +1-317-655-8808, pager: +1-888-
462-2576, [email protected]
-0- May/24/2005 19:00 GMT
2005-05-24 15:00 (New York)
Relief for Up to 24 Hours
Data Showed that Morning and Evening Dosing Produced Similar Results
ATLANTA, Ga., May 24 /PRNewswire-FirstCall/ -- Once-daily treatment with
atomoxetine HCl, approved for the treatment of Attention-Deficit/Hyperactivity
Disorder (ADHD), produced core symptom reductions in children and, in a
secondary analysis, were sustained up to 24 hours according to a study
presented today at the 158th annual meeting of the American Psychiatric
Association.
Atomoxetine was dosed in either the morning or the evening. This study
found morning or evening dosing produced similar core symptom reduction based
on the ADHD-RS, a scale which assesses 18 individual symptoms related to ADHD
(nine assess inattentive symptoms and the other nine assess hyperactive and
impulsive symptoms). This is the second placebo-controlled study that found
atomoxetine was effective in providing continuous symptom relief in children.
"Atomoxetine's ability to control symptoms of ADHD demonstrated in this
study for up to 24 hours provides physicians with a flexible option for
treating ADHD in children," said Humberto Quintana, Associate Professor of
Psychiatry, Louisiana State University School of Medicine at New Orleans, and
a lead investigator on the study.
Additional Study Results
* Both morning and evening dosing produced significantly greater
decreases than placebo at endpoint on the following scales:
- ADHDRS total score: 17.76 (41 percent) improvement with morning
dosing, 13.45 (32 percent) improvement with evening dosing, vs. 9.51 (22
percent) with placebo. Overall comparison with placebo p<.001 for morning
dosing, p=.009 for evening dosing.
- Daily Parent Rating of Evening and Morning Behavior-Revised Scale
Total (DPREMB-R), a secondary analysis: 3.61 (26 percent) improvement with
morning dosing, 4.85 (32 percent) improvement with evening dosing vs. 2.66 (17
percent) improvement with placebo. Overall comparison with placebo p=.028 for
morning dosing, p=.023 for evening dosing.
- Conners' Global Index: Parent-Morning scale (CGIP-M) Total, a
secondary analysis: 5.62 (34 percent) improvement with morning dosing, 6.02
(39 percent) improvement with evening dosing vs. 4.10 (26 percent) improvement
with placebo. Overall comparison with placebo p=.023 for morning dosing,
p=.024 for evening dosing.
- Conners' Global Index: Parent-Evening scale (CGIP-E) Total: 5.82 (31
percent) improvement with morning dosing, 4.46 (23 percent) improvement with
evening dosing vs. 2.03 (11 percent) improvement with placebo. Overall
comparison with placebo p<.001 for morning dosing, p=.002 for evening dosing.
* The most common treatment adverse events reported for patients on
atomoxetine included upper abdominal pain, decreased appetite, vomiting,
headache, somnolence, nausea and stomach discomfort.
"Atomoxetine offers the convenience of morning or evening dosing, allowing
parents to work with physicians to decide what dosing regimen best fits into
their child's daily routine," said Douglas Kelsey, MD, Senior Research
Physician, Eli Lilly and Company.
Methods
* 288 children (aged 6-12) were randomized to receive atomoxetine in the
morning and placebo in the evening (n=102), placebo in the morning and
atomoxetine in the evening (n=93) or placebo in the morning and evening (n=93)
for approximately six weeks. (Approved dosing is once or twice daily).
* Patients receiving atomoxetine (n=195) had a starting dose of
8mg/kg/day for three days and increased to the target dose of 1.2 mg/kg/day
thereafter. Maximum dose was 1.4 mg/kg/day but did not exceed 100mg
regardless of patient's weight. (Approved starting label dose is 0.5mg/kg/day
for children and adolescents up to 70kg).
* Parent assessments of children's home behaviors in the evening and
early morning were collected using the DPREMB-R and CGIP-M and CGIP-E scales.
About ADHD
ADHD affects three - seven percent of school-age children and manifests
itself in levels of attention, concentration, activity, distractibility and
impulsivity that are inappropriate to the child's age.(1) In addition, 60
percent of children with the disorder carry their symptoms into adulthood.(2)
Experts estimate four percent of adults in the United States, more than eight
million people, have ADHD.(3,4)
About Atomoxetine
Atomoxetine, a selective norepinephrine reuptake inhibitor, is approved to
treat ADHD in children aged six and over, adolescents, and adults. It is not
known precisely how atomoxetine reduces ADHD symptoms, but scientists believe
it works by blocking or slowing reabsorption of norepinephrine, a chemical in
the brain considered important in regulating attention, impulsivity and
activity levels. This keeps more norepinephrine at work in the spaces between
neurons in the brain. Improved efficiency in the norepinephrine system is
associated with improvement in symptoms of ADHD (Pliska, 1996).
Atomoxetine should not be taken at the same time as, or within two weeks
of taking, a monoamine oxidase inhibitor (MAOI) or by patients with narrow
angle glaucoma. Patients with a history of high or low blood pressure,
increased heart rate, or any heart or blood vessel disease should tell their
doctor before taking atomoxetine. Atomoxetine has not been tested in children
less than six years of age or in geriatric patients. Some children may lose
weight when starting treatment with atomoxetine. As with all ADHD
medications, growth should be monitored during treatment. Atomoxetine can
cause liver damage in rare cases. Patients should tell their doctor right
away if they have itching, dark urine, yellow skin/eyes, upper right-sided
abdominal tenderness, or unexplained "flu-like" symptoms.
Most people in clinical studies who experienced side effects were not
bothered enough to stop using atomoxetine. The most common side effects in
children and adolescents in medical studies were upset stomach, decreased
appetite, nausea and vomiting, dizziness, tiredness and mood swings. In
adults, the most common side effects were constipation, dry mouth, nausea,
decreased appetite, dizziness, problems sleeping, sexual side effects,
problems urinating and menstrual cramps.
About Lilly
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered in
Indianapolis, Ind., Lilly provides answers -- through medicines and
information -- for some of the world's most urgent medical needs. Additional
information about Lilly is available at www.lilly.com .
P-LLY
(1) American Psychiatric Association: Diagnostic and Statistical Manual
of Mental Disorders, fourth edition, text revision, Washington, DC, American
Psychiatric Association, 2000.
(2) Schweitzer JB, et al. Attention-deficit/hyperactivity disorder. Med
Clin of North Am. 2001; 85(3): 757-777
(3) Murphy K, Barkley, RA. J Atten disord. 1996; 1:147-161.
(4) United States Census Summary File; 2000.
(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )
SOURCE Eli Lilly and Company
CONTACT:
Jennifer Bunselmeyer of Eli Lilly and Company, +1-317-655-8808, pager: +1-888-
462-2576, [email protected]
-0- May/24/2005 19:00 GMT